2021 Was a Big Year for Arcutis: FDA accepts New Drug Application for review for novel
NEW CAMPAIGN FROM ARCUTIS AIMS TO EXPOSE THE IMPACT OF PSORIASIS ON PHYSICAL, MENTAL, AND EMOTIONAL WELLBEING
arcutispressreleaseburro
Arcutis Biotherapeutics Unveils Vesting Schedule for Restricted Stock Units
Arcutis Biotherapeutics Company Profile: Stock Performance & Earnings | PitchBook
Arcutis Biotherapeutics, Inc. (ARQT) Stock Price, Quote & News - Stock Analysis
FDA Action Alert: Vertex/CRISPR, Arcutis and Optinose | BioSpace
Does The Encouraging Reception For Zoryve Signal Exciting Times For Arcutis?
FDA Approves Arcutis' ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older - Arcutis Biotherapeutics
Mohamed Alyami on X: "#معلومة حصلت شركة Arcutis Biotherapeutics Inc. على موافقة إدارة الغذاء والدواء الأمريكية (FDA) على دواءها المطور حديثًا #roflumilast #Zoryve، المصمم لمعالجة التهاب الجلد الدهني (seborrheic dermatitis). Zoryve هو
Arcutis Biotherapeutics
Archive | Fiji Industry Times
News & Media - Arcutis Biotherapeutics
Arcutis Appoints L. Todd Edwards as Chief Commercial
MyHealthTeam and Arcutis Biotherapeutics Launch New Social Network for People Living with Seborrheic Dermatitis
Arcutis Announces Addition of Three Senior Executives to Management Team
Arcutis Biotherapeutics, Inc.
Arcutis Announces Addition of Three Senior Executives to Management Team
Arcutis Biotherapeutics' (ARQT) "Buy" Rating Reiterated at Mizuho - MarketBeat
Arcutis' Zoryve bags 2nd FDA nod, this time as a foam to treat 'the great neglected disease in dermatology' | Fierce Pharma
ARQT Arcutis Biotherapeutics Stock Data, Filings, Earnings, News & Transcripts
FDA approves Arcutis' skin foam for seborrheic dermatitis
